Kalohexis Files Confidentially for IPO to Fund Obesity, Cachexia Drugs
Clinical-stage biotech Kalohexis seeks public listing to advance therapies targeting obesity and cancer cachexia via melanocortin system modulation. Kalohexis has confidentially filed for an initial public offering (IPO) with the US Securities and Exchange Commission, aimi